Get the Stockscreener App
18.06
3.38%
-0.59
Immunome Inc stock is traded at $18.06, with a volume of 431.19K.
It is down -3.38% in the last 24 hours and up +14.85% over the past month.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
See More
Previous Close:
$18.65
Open:
$18.86
24h Volume:
431.19K
Relative Volume:
0.30
Market Cap:
$1.65B
Revenue:
$12.59M
Net Income/Loss:
$-212.39M
P/E Ratio:
-5.8536
EPS:
-3.0853
Net Cash Flow:
$-185.92M
1W Performance:
+0.90%
1M Performance:
+14.85%
6M Performance:
+112.25%
1Y Performance:
+61.61%
1-Day Range:
$17.96
$19.13
1-Week Range:
$17.30
$19.16
52-Week Range:
$5.1501
$19.16
Immunome Inc Stock (IMNM) Company Profile
Name
Immunome Inc
Sector
Industry
Phone
610-321-3700
Address
18702 N. CREEK PARKWAY, BOTHELL
Compare IMNM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
18.03 | 1.71B | 12.59M | -212.39M | -185.92M | -3.0853 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.20 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.88 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.18 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
908.04 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.44 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-22-25 | Initiated | Goldman | Buy |
| Sep-05-25 | Initiated | Craig Hallum | Buy |
| Apr-02-25 | Initiated | Lake Street | Buy |
| Nov-08-24 | Initiated | Stephens | Overweight |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Apr-30-24 | Initiated | JP Morgan | Overweight |
| Apr-15-24 | Initiated | Guggenheim | Buy |
| Jan-29-24 | Initiated | Leerink Partners | Outperform |
| Dec-19-23 | Initiated | Wedbush | Outperform |
| Oct-29-21 | Initiated | Cantor Fitzgerald | Overweight |
View All
Immunome Inc Stock (IMNM) Latest News
Immunome Inc (IMNM) is looking forward to a strong quarter - Setenews
Immunome to Present at Upcoming Investor Conferences - MarketScreener
Immunome (NASDAQ:IMNM) Upgraded at Wall Street Zen - Defense World
Immunome stock hits 52-week high at $18.79 By Investing.com - Investing.com Nigeria
Immunome stock hits 52-week high at $18.79 - Investing.com
Will Immunome Inc. stock attract more institutional investorsEarnings Overview Summary & Fast Momentum Stock Entry Tips - newser.com
What technical signals suggest for Immunome Inc. stockEarnings Overview Summary & AI Driven Stock Movement Reports - newser.com
How Immunome Inc. stock benefits from tech adoptionTrade Analysis Summary & Short-Term Trading Alerts - newser.com
Will Immunome Inc. stock outperform value stocks2025 Geopolitical Influence & Weekly Top Performers Watchlists - newser.com
Is Immunome Inc. stock a safe haven assetGDP Growth & Weekly Top Gainers Trade List - newser.com
Is Immunome Inc. stock bottoming out2025 Bull vs Bear & Risk Controlled Stock Pick Alerts - newser.com
Immunome (NASDAQ:IMNM) Stock Price Expected to Rise, Stephens Analyst Says - Defense World
Can swing trading help recover from Immunome Inc. lossesJuly 2025 Action & Daily Volume Surge Signals - newser.com
Lake Street Sticks to Their Buy Rating for Immunome (IMNM) - The Globe and Mail
Discipline and Rules-Based Execution in IMNM Response - news.stocktradersdaily.com
Stephens raises Immunome stock price target to $33 on varegacestat potential - Investing.com Nigeria
IMNM Analyst Rating Update: Stephens & Co. Raises Price Target | - GuruFocus
Immunome price target raised to $33 from $25 at Stephens - TipRanks
Is Immunome’s (IMNM) Improved Efficiency a Sign of Lasting Strength in the Biotech Race? - simplywall.st
Can Immunome Inc. stock deliver surprise earnings beat2025 Buyback Activity & Expert Curated Trade Setup Alerts - newser.com
Historical volatility pattern of Immunome Inc. visualizedQuarterly Risk Review & Weekly Top Gainers Trade List - newser.com
What drives Immunome Inc stock priceSmall Cap Stock Opportunities & Free Daily Market Summary and Trend Reports - earlytimes.in
What Makes Escorts Kubota Limited a Resilient Investment During CrisesCash Flow Trends & Master Timing Market Moves - earlytimes.in
Immunome stock hits 52-week high at 17.89 USD By Investing.com - Investing.com Canada
How Immunome Inc. stock performs in rate cut cyclesMarket Weekly Review & AI Powered Market Entry Ideas - newser.com
Immunome stock hits 52-week high at 17.89 USD - Investing.com
Will Immunome Inc. stock reach Wall Street targetsQuarterly Investment Review & High Conviction Investment Ideas - newser.com
Immunome, Inc. Reports Q3 2025 Financial Results - TipRanks
Immunome Inc Stock (IMNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunome Inc Stock (IMNM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BIENAIME JEAN JACQUES | Director |
Jun 03 '25 |
Buy |
9.38 |
5,000 |
46,900 |
36,415 |
| Higgins Jack | Chief Scientific Officer |
Mar 27 '25 |
Option Exercise |
1.35 |
5,200 |
7,020 |
18,729 |
| BIENAIME JEAN JACQUES | Director |
Mar 25 '25 |
Buy |
7.78 |
7,800 |
60,684 |
31,415 |
| SIEGALL CLAY B | President and CEO |
Mar 26 '25 |
Buy |
7.29 |
137,100 |
999,459 |
806,736 |
| BIENAIME JEAN JACQUES | Director |
Mar 24 '25 |
Buy |
8.21 |
7,000 |
57,470 |
23,615 |
| Tsai Philip | Chief Technology Officer |
Mar 24 '25 |
Buy |
8.42 |
12,300 |
103,566 |
33,300 |
| SIEGALL CLAY B | President and CEO |
Jan 31 '25 |
Buy |
7.75 |
150,000 |
1,162,500 |
669,636 |
0.50%
1.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):